Elder Pharmaceuticals Peer Comparison

NSE: ELDERPHARM | BSE: 532322

₹38.00

₹1.80 (4.97%)

As on 12-Sep-2016IST

Market cap

₹78 Cr

Revenue (TTM)

₹633 Cr

P/E Ratio

P/B Ratio

0.1

Div. Yield

0 %

Edit

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Market cap (₹ Cr)	78	30,978	25,888	26,649	24,655
Revenue (₹ Cr)	633	3,564	9,205	1,462	1,936
Net Profit (₹ Cr)	-79.91	414.00	-371.81	387.35	288.22
Net Margin (%)	-12.35	11.23	-3.93	26.01	14.79
RoE (%)	-61.43	8.38	-3.85	25.18	29.77
Price to Earnings	--	75.74	--	69.00	85.54
Price-To-Book	0.12	6.15	3.23	15.45	18.37

Income Statement (₹ Cr)

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Operating Revenue	1,008.91	4,830.36	--	76.11	41.58
Total Income	1,034.57	4,914.64	--	76.68	41.73
Total Expenditure	1,088.10	3,850.53	--	69.99	30.00
EBITDA	-79.19	979.83	--	6.12	11.59
Depreciation	36.13	139.92	--	0.80	3.35
EBIT	-115.31	839.91	--	5.32	8.24
Interest	275.63	83.35	--	1.58	2.34
Other Income	25.66	84.28	--	0.56	0.14
Exceptional Items	371.27	49.83	--	--	--
Profit before Tax	5.99	890.67	--	4.31	6.04
Provision for Tax	12.52	47.88	--	1.44	1.54
Profit after Tax	-6.53	842.79	--	2.86	4.50

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Shareholder's Funds	773.35	3,581.47	--	10.77	44.83
Minority Interest	--	136.17	--	--	--
Non-Current Liabilities	515.08	1,161.18	--	1.29	10.36
Current Liabilities	999.77	1,743.20	--	26.33	21.34
Total Liabilities	2,288.20	6,622.02	--	38.71	76.53

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Non-Current Assets	1,364.20	3,266.10	--	7.38	51.75
Current Assets	924.00	3,355.92	--	31.01	24.78
Total Assets	2,288.20	6,622.02	--	38.71	76.53
Total Debt*	847.62	1,906.08	--	12.17	21.09
Net Current Assets	-75.77	1,612.72	--	4.68	3.44
Contingent Liabilities	157.84	267.40	--	--	4.70

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Cash From Operating Activities	1,175.41	1,476.29	--	-0.21	6.29
Cash Flow from Investing Activities	-56.05	-851.62	--	-2.00	-5.46
Cash from Financing Activities	-676.18	-601.32	--	2.17	-0.58
Net Cash Inflow / Outflow	443.17	23.35	--	-0.04	0.25

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
ROCE (%)	15.08	18.98	--	29.97	13.38
ROE (%)	-0.85	30.04	--	30.26	19.08
ROA (%)	-0.27	13.36	--	8.85	6.16
EBIT Margin (%)	-5.31	22.03	--	8.78	28.21
Net Margin (%)	-0.63	17.15	--	3.74	10.78
Cash Profit Margin (%)	2.92	20.32	--	4.81	18.86

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Revenue Growth (%)	-38.54	-13.89	--	37.10	12.11
EBIT Growth (%)	-117.49	-49.66	--	30.95	21.82
Net Profit Growth (%)	-107.93	-46.64	--	39.55	58.36
EPS Growth (%)	-107.93	-56.04	--	39.55	58.36
Book Value Growth (%)	0.53	36.37	--	32.03	21.09

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Price / Earnings	0.00	6.59	--	0.00	0.00
Price / Book Value	0.58	1.55	--	0.00	0.00
Dividend Yield (%)	0.00	2.19	--	--	--
EV/EBITDA	-13.97	5.73	--	2.02	3.52
Market Cap (₹ Cr)	446.78	5,016.58	--	0.00	0.00

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debt to Equity	1.10	0.54	--	1.13	0.47
Short term debt to equity ratio	0.34	0.06	--	0.84	0.23
Current Ratio	0.92	1.93	--	1.18	1.16
Quick Ratio	0.81	1.36	--	0.75	1.11
Interest Coverage	1.02	11.69	--	3.73	3.58

	Elder Pharmaceuticals	Wockhardt	Piramal Pharma	Acutaas Chemicals	Rubicon Research
Debtors to sales (%)	16.42	9.96	--	17.81	33.85
Asset Turnover	0.42	0.77	--	2.35	0.57
Receivable days	101.58	54.33	--	58.46	106.93
Inventory Days	67.21	77.43	--	41.85	10.49
Payable days	61.48	120.43	--	91.25	213.33
Cash Conversion Cycle	107.30	11.32	--	9.06	-95.91

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.